Khalid et al., 2020 - Google Patents
Fibroblast growth factor receptor 3 mutation as a prognostic indicator in patients with urothelial carcinoma: a systematic review and meta-analysisKhalid et al., 2020
View HTML- Document ID
- 14278834897377403626
- Author
- Khalid S
- Basulaiman B
- Emack J
- Booth C
- Duran I
- Robinson A
- Berman D
- Smoragiewicz M
- Amir E
- Vera-Badillo F
- Publication year
- Publication venue
- European Urology Open Science
External Links
Snippet
Background Fibroblast growth factor receptor 3 (FGFR3) mutations have been implicated in urothelial tumorigenesis. FGFR3 inhibitors are being explored in clinical trials. Objective We aimed to study the association between FGFR3 mutations and survival in urothelial …
- 108010081267 Type 3 Fibroblast Growth Factor Receptor 0 title abstract description 85
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Hybridisation probes
- C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
- C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wang et al. | Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer | |
Li et al. | Adenosquamous carcinoma of the lung | |
Ferraldeschi et al. | PTEN protein loss and clinical outcome from castration-resistant prostate cancer treated with abiraterone acetate | |
Labianca et al. | Colon cancer | |
Grivas et al. | The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches | |
Karapetis et al. | K-ras mutations and benefit from cetuximab in advanced colorectal cancer | |
Safaee Ardekani et al. | The prognostic value of BRAF mutation in colorectal cancer and melanoma: a systematic review and meta-analysis | |
Labianca et al. | Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up | |
Pichler et al. | miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor | |
Kolling et al. | “Metastatic cancer of unknown primary” or “primary metastatic cancer”? | |
Falato et al. | Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer | |
Thompson et al. | Receptor tyrosine kinase expression profiles in canine cutaneous and subcutaneous mast cell tumors | |
Capdevila et al. | Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets | |
Bueno et al. | Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (alliance) | |
Pagani et al. | Collecting ducts carcinoma: An orphan disease. Literature overview and future perspectives | |
Seedor et al. | Genetic landscape and emerging therapies in uveal melanoma | |
Hamada et al. | Vitamin D status after colorectal cancer diagnosis and patient survival according to immune response to tumour | |
Hutchins et al. | Intratumoral stromal morphometry predicts disease recurrence but not response to 5‐fluorouracil—results from the QUASAR trial of colorectal cancer | |
Rutkowski et al. | Extended adjuvant therapy with imatinib in patients with gastrointestinal stromal tumors: recommendations for patient selection, risk assessment, and molecular response monitoring | |
Bellmunt et al. | Molecular targets on the horizon for kidney and urothelial cancer | |
Wu et al. | Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma | |
Bergot et al. | Predictive biomarkers in patients with resected non-small cell lung cancer treated with perioperative chemotherapy | |
Allegrini et al. | Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab | |
Alshalalfa et al. | Transcriptomic and clinical characterization of neuropeptide Y expression in localized and metastatic prostate cancer: identification of novel prostate cancer subtype with clinical implications | |
Di Leo et al. | Topoisomerase II alpha as a marker predicting anthracyclines’ activity in early breast cancer patients: ready for the primetime? |